PharmaShots | Incisive News in 3 Shots

Subscribe Now

novartis

Monte Rosa Therapeutics and Novartis Collaborate to Advance VAV1-directed Molecular Glue Degraders (MGD)

Monte Rosa Therapeutics and Novartis Collaborate to Advance VAV1-directed Molecular Glue Degraders (MGD)

October 29, 2024

Novartis Reports Data from P-III (APPEAR-C3G) Study of Fabhalta (Iptacopan) in C3 Glomerulopathy (C3G)

Novartis Reports Data from P-III (APPEAR-C3G) Study of Fabhalta (Iptacopan) in C3 Glomerulopathy (C3G)

October 28, 2024

Novartis’ Kisqali (Ribociclib) Gains the CHMP’s Positive Opinion as an Adjuvant Treatment of HR+/HER2- Early Breast Cancer (EBC)

Novartis’ Kisqali (Ribociclib) Gains the CHMP’s Positive Opinion as an Adjuvant Treatment of HR+/HER2- Early Breast Cancer (EBC)

October 18, 2024

PharmaShots Weekly Snapshots (September 16 – September 20, 2024)

PharmaShots Weekly Snapshots (September 16 – September 20, 2024)

September 20, 2024

Novartis Reports the US FDA’s Approval of Kisqali (Ribociclib) for the Treatment of HR+/HER2- Early Breast Cancer

Novartis Reports the US FDA’s Approval of Kisqali (Ribociclib) for the Treatment of HR+/HER2- Early Breast Cancer

September 18, 2024

Novartis to Highlight Updated Data from the P-III (NATALEE) Study of Kisqali (Ribociclib) for Treating Early Breast Cancer (EBC) at ESMO 2024

Novartis to Highlight Updated Data from the P-III (NATALEE) Study of Kisqali (Ribociclib) for Treating Early Breast Cancer (EBC) a...

September 16, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us